Anika Therapeutics Business Summary

Anika Therapeutics, Inc. (ANIK) is a global leader in early-intervention orthopedics, specializing in the development and commercialization of therapeutic products based on its proprietary hyaluronic acid (HA) technology platform. The company generates revenue through two primary distribution channels: its Commercial Channel, which utilizes a direct sales force to market regenerative solutions and international osteoarthritis (OA) pain products, and its OEM Channel, which earns royalties and transfer fees through long-term partnerships, most notably with Johnson & Johnson’s MedTech division for the Monovisc and Orthovisc product lines. Its business is segmented into OA Pain Management, featuring the next-generation steroid-combination injection Cingal, and Regenerative Solutions, anchored by the high-growth Integrity Implant System for tendon repair. Anika competes directly with specialized orthopedic and medical device firms such as Orthofix Medical, Annovis Bio, and Utah Medical Products, positioning itself as a high-density niche player focused on joint preservation and tissue restoration rather than total joint replacement. Leadership is currently spearheaded by President and CEO Stephen (Steve) Griffin, who assumed the role on February 1, 2026, after serving as the company’s CFO and COO; he brings extensive operational experience from VSE Corporation and a decade-long tenure at General Electric. Griffin is supported by Executive Chair Cheryl R. Blanchard, Ph.D., the former CEO and a veteran of Zimmer Biomet, and Ian McLeod, who serves as Senior Vice President and Chief Accounting Officer. The company’s strategic direction is heavily influenced by its Board of Directors, which includes Lead Independent Director John (Jack) B. Henneman, III, and former executives from industry giants like Stryker (William Jellison) and Johnson & Johnson (Gary Fischetti). Notable institutional backing includes healthcare-focused activist investor Caligan Partners, which has been instrumental in driving the company’s recent shift toward financial discipline and the divestiture of non-core assets to maximize shareholder value.